ViiV to use Halozyme tech for long-acting HIV drugs

22 June 2021

HIV specialist ViiV Healthcare and Halozyme Therapeutics (Nasdaq: HALO) have announced a global collaboration and license agreement related to the latter’s Enhanze drug delivery technology.

The deal will see ViiV leverage the recombinant human hyaluronidase PH20 enzyme for specific targets in the treatment and prevention of HIV.

Under the terms of the deal, ViiV will make an upfront payment of $40 million to Halozyme for the exclusive license to four HIV small and large molecule targets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK